Overview

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors plan cancer treatment. PURPOSE: This study is looking at brain function in premenopausal women who are receiving adjuvant tamoxifen (T) alone against those receive adjuvant tamoxifen (T+OFS) or exemestane (E+OFS) with ovarian function suppression (OFS) for early-stage breast cancer on clinical trial IBCSG-2402.

Phase:

Phase 3

Details

Lead Sponsor:

International Breast Cancer Study Group

Collaborators:

Australia and New Zealand Breast Cancer Trials Group
Breast Cancer Trials, Australia and New Zealand
Cancer and Leukemia Group B
National Cancer Institute (NCI)

Treatments:

Exemestane
Tamoxifen
Triptorelin Pamoate